Replies to post #19400 on Ariad Pharmaceuticals Inc fka ARIA

[micanwait]

Binch..

Let' see -- Ponatanib or Tasigna? Hmmm... WWOD (What would the oncologist do?)

---

My favorite point from the Cramer interview: Peak revenue from Ponatanib will be $2.5 billion/year for CML alone. (note he said that patients would take a pill/day for many years)

Harvey gives great interview. He knows what a favorite Celgene has been with Cramer and Harvey made a point of saying, in effect, this is the next Celgene.

His interview skills are just one more reason why the Harvey bashers on this board -- of which there are fewer of late -- are nuts.